<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37216955</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2619</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Lancet. Respiratory medicine</Title><ISOAbbreviation>Lancet Respir Med</ISOAbbreviation></Journal><ArticleTitle>Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation.</ArticleTitle><Pagination><StartPage>709</StartPage><EndPage>725</EndPage><MedlinePgn>709-725</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-2600(23)00159-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-2600(23)00159-5</ELocationID><Abstract><AbstractText>Although the exact prevalence of post-COVID-19 condition (also known as long COVID) is unknown, more than a third of patients with COVID-19 develop symptoms that persist for more than 3 months after SARS-CoV-2 infection. These sequelae are highly heterogeneous in nature and adversely affect multiple biological systems, although breathlessness is a frequently cited symptom. Specific pulmonary sequelae, including pulmonary fibrosis and thromboembolic disease, need careful assessment and might require particular investigations and treatments. COVID-19 outcomes in people with pre-existing respiratory conditions vary according to the nature and severity of the respiratory disease and how well it is controlled. Extrapulmonary complications such as reduced exercise tolerance and frailty might contribute to breathlessness in post-COVID-19 condition. Non-pharmacological therapeutic options, including adapted pulmonary rehabilitation programmes and physiotherapy techniques for breathing management, might help to attenuate breathlessness in people with post-COVID-19 condition. Further research is needed to understand the origins and course of respiratory symptoms and to develop effective therapeutic and rehabilitative strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Sally J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory and Infectious Diseases, Leicester, UK. Electronic address: ss1119@le.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Molly M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory and Infectious Diseases, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daynes</LastName><ForeName>Enya</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory and Infectious Diseases, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Rachael A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory and Infectious Diseases, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greening</LastName><ForeName>Neil J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory and Infectious Diseases, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>R Gisli</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Imperial College London National Heart and Lung Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lone</LastName><ForeName>Nazir I</ForeName><Initials>NI</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Critical Care and Pain Medicine, Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAuley</LastName><ForeName>Hamish</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory and Infectious Diseases, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Puja</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Inflammation and Tissue Repair, Division of Medicine, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novotny</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory and Infectious Diseases, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>David J F</ForeName><Initials>DJF</Initials><AffiliationInfo><Affiliation>Royal Brompton and Harefield Hospitals, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanel</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Manchester University NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toshner</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NIHR Cambridge Biomedical Research Centre, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brightling</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory and Infectious Diseases, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/W006111/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Respir Med</MedlineTA><NlmUniqueID>101605555</NlmUniqueID><ISSNLinking>2213-2600</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Respir Med. 2023 Aug;11(8):667-668. doi: 10.1016/S2213-2600(23)00232-1</RefSource><PMID Version="1">37475126</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011658" MajorTopicYN="Y">Pulmonary Fibrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests SJS has received project funding from the UK National Institute for Health Research (NIHR), UK Research and Innovation, the Department of Health and Social Care, and Actegy. She has received funding for a doctoral training programme from the Wellcome Trust, and reports funding for presentations from GSK, the UK Ministry of Justice, Cipla, and Sherbourne Gibbs. SJS is the American Thoracic Society Pulmonary Rehabilitation Assembly Chair, clinical lead for the Royal College of Physicians Pulmonary Rehabilitation Accreditation Scheme, clinical lead for the National Asthma and COPD Audit Programme for Pulmonary Rehabilitation, and is on the National Institute for Health and Care Excellence expert advisory panel for long COVID. CEB has received funding to his institution for consultancy and investigator roles from GSK, AstraZeneca, Genentech, Roche, Sanofi, Regeneron, Boehringer Ingelheim, Chiesi, Mologic, and 4DPharma. RAE reports research funding from the NIHR, UKRI, and the Wolfson Foundation. She has received payment for a consultancy role from AstraZeneca, for invited lectures from Boehringer Ingelheim, and for conference attendance from Chiesi. RAE is secretary of the European Respiratory Society Group 01.02 Rehabilitation and Chronic Care. RGJ has received grants to his institution from AstraZeneca, Biogen, Galecto, GSK, Nordic Biosciences, RedX, and Pilant. He reports consultancy fees from AstraZeneca, Brainomix, Bristol Myers Squibb, Chiesi, Cohbar, Daewoong, GSK, Pliant, Resolution Therapeutics, Roche, and Veracyte, and lecture fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Roche, and PatientMPower. RGJ is on data safety monitoring boards for Boehringer Ingelheim, Galapagos, and Vicore, and is on the advisory board of NuMedii. RGJ is the current president of Action for Pulmonary Fibrosis. MT has received funding from MorphogenIX and Jansen for taking part in advisory boards and has received support from GSK and Jansen to travel and attend meetings. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37216955</ArticleId><ArticleId IdType="pmc">PMC10198676</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(23)00159-5</ArticleId><ArticleId IdType="pii">S2213-2600(23)00159-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>John Hopkins University &amp; Medicine  John Hopkins Coronavirus Resource Centre &#x2013; COVID-19 Dashboard. https://coronavirus.jhu.edu/map.html</Citation></Reference><Reference><Citation>Office for National Statistics  Coronavirus (COVID-19) latest insights: hospitals. March 28, 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals</Citation></Reference><Reference><Citation>Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26:1770&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pubmed">35302230</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Health and Care Excellence  COVID-19 rapid guideline: managing COVID-19. NICE Guideline (NG191) March 23, 2021. https://www.nice.org.uk/guidance/NG191</Citation><ArticleIdList><ArticleId IdType="pubmed">34181371</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiris JS, Yuen KY, Osterhaus AD, St&#xf6;hr K. The severe acute respiratory syndrome. N Engl J Med. 2003;349:2431&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntley CC, Patel K, Bil Bushra S-E-S, et al. Pulmonary function test and computed tomography features during follow-up after SARS, MERS and COVID-19: a systematic review and meta-analysis. ERJ Open Res. 2022;8:00056&#x2013;02022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035766</ArticleId><ArticleId IdType="pubmed">35642193</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation  Post COVID-19 condition (long COVID) Dec 7, 2022. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition</Citation></Reference><Reference><Citation>Office for National Statistics  Self-reported long COVID after infection with the omicron variant in the UK: 18 July 2022. Jul 18, 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/18july2022</Citation></Reference><Reference><Citation>The PHOSP-COVID Collaborative Group Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10:761&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryden M, Mudara C, Vika C, et al. Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health. 2022;10:e1247&#x2013;e1256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9363040</ArticleId><ArticleId IdType="pubmed">35961348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud R, Rahman MM, Rassel MA, et al. Post-COVID-19 syndrome among symptomatic COVID-19 patients: a prospective cohort study in a tertiary care center of Bangladesh. PLoS One. 2021;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8031743</ArticleId><ArticleId IdType="pubmed">33831043</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake TM, Docherty AB, Harrison EM, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med. 2020;202:1656&#x2013;1665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737581</ArticleId><ArticleId IdType="pubmed">33007173</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachroo P, Stewart ID, Kelly RS, et al. Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma. Nat Med. 2022;28:814&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350737</ArticleId><ArticleId IdType="pubmed">35314841</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S, Cortese M, Winter SL, et al. SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. Nat Commun. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7676268</ArticleId><ArticleId IdType="pubmed">33208793</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881. 95.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S, Abbafati C, Aerts JG, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2022;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Florencio LL, Fern&#xe1;ndez-de-Las-Pe&#xf1;as C. Long COVID: systemic inflammation and obesity as therapeutic targets. Lancet Respir Med. 2022;10:726&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034853</ArticleId><ArticleId IdType="pubmed">35472305</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, et al. Features of 20&#x2008;133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiumello D, Taccone P, Berto V, et al. Long-term outcomes in survivors of acute respiratory distress syndrome ventilated in supine or prone position. Intensive Care Med. 2012;38:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">22187085</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry SM, Nalamalapu SR, Nunna K, et al. Six-minute walk distance after critical illness: a systematic review and meta-analysis. J Intensive Care Med. 2021;36:343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442114</ArticleId><ArticleId IdType="pubmed">31690160</ArticleId></ArticleIdList></Reference><Reference><Citation>Davydow DS, Desai SV, Needham DM, Bienvenu OJ. Psychiatric morbidity in survivors of the acute respiratory distress syndrome: a systematic review. Psychosom Med. 2008;70:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10885706</ArticleId><ArticleId IdType="pubmed">18434495</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA. 1999;281:354&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">9929089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamdar BB, Suri R, Suchyta MR, et al. Return to work after critical illness: a systematic review and meta-analysis. Thorax. 2020;75:17&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418481</ArticleId><ArticleId IdType="pubmed">31704795</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron JI, Chu LM, Matte A, et al. One-year outcomes in caregivers of critically ill patients. N Engl J Med. 2016;374:1831&#x2013;1841.</Citation><ArticleIdList><ArticleId IdType="pubmed">27168433</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart I, Jacob J, George PM, et al. Residual lung abnormalities following COVID-19 hospitalization: interim analysis of the UKILD post-COVID study. Am J Respir Crit Care Med. 2022;207:693&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037479</ArticleId><ArticleId IdType="pubmed">36457159</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgel P-R, Goss C. COVID-19 outcomes in people with cystic fibrosis. Curr Opin Pulm Med. 2021;27:538&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575136</ArticleId><ArticleId IdType="pubmed">34620788</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Cao Y, Du T, Zhi Y. Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2021;9:693&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725230</ArticleId><ArticleId IdType="pubmed">33309934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng CK, Chan JW, Kwan TL, et al. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors. Thorax. 2004;59:889&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1746851</ArticleId><ArticleId IdType="pubmed">15454656</ArticleId></ArticleIdList></Reference><Reference><Citation>Das KM, Lee EY, Al Jawder SE, et al. Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients. AJR Am J Roentgenol. 2015;205:W267&#x2013;W274.</Citation><ArticleIdList><ArticleId IdType="pubmed">26102309</ArticleId></ArticleIdList></Reference><Reference><Citation>Orme J, Jr, Romney JS, Hopkins RO, et al. Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2003;167:690&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Rosas IO, Singer M. Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity. Intensive Care Med. 2022;48:1803&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9453725</ArticleId><ArticleId IdType="pubmed">36074167</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H, Qin Z, Geng B, et al. Impaired lung regeneration after SARS-CoV-2 infection. Cell Prolif. 2020;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645888</ArticleId><ArticleId IdType="pubmed">33078459</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurink B, Roos E, Radonic T, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020;1:e290&#x2013;e299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7518879</ArticleId><ArticleId IdType="pubmed">33015653</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbin MR, Mehta A, Schneider AM, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. 2021;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091031</ArticleId><ArticleId IdType="pubmed">33969320</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID-19: A systematic review. PLoS One. 2021;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8081217</ArticleId><ArticleId IdType="pubmed">33909679</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman DE, Mehta A, Thompson BT, et al. Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19. Am J Respir Crit Care Med. 2022;205:507&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906476</ArticleId><ArticleId IdType="pubmed">34878969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38:970&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">32591762</ArticleId></ArticleIdList></Reference><Reference><Citation>Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2010;4:367&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">20952439</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen RJ, Guillen-Guio B, Croot E, et al. Genetic overlap between idiopathic pulmonary fibrosis and COVID-19. Eur Respir J. 2022;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9130756</ArticleId><ArticleId IdType="pubmed">35595312</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen RJ, Stockwell A, Oldham JM, et al. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax. 2022;77:829&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9329250</ArticleId><ArticleId IdType="pubmed">35688625</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatler AL, Jenkins G. TGF-&#x3b2; activation and lung fibrosis. Proc Am Thorac Soc. 2012;9:130&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">22802287</ArticleId></ArticleIdList></Reference><Reference><Citation>Morganstein T, Haidar Z, Trivlidis J, et al. Involvement of the ACE2/Ang-(1-7)/MasR axis in pulmonary fibrosis: implications for COVID-19. Int J Mol Sci. 2021;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8657555</ArticleId><ArticleId IdType="pubmed">34884756</ArticleId></ArticleIdList></Reference><Reference><Citation>Melms JC, Biermann J, Huang H, et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021;595:114&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814825</ArticleId><ArticleId IdType="pubmed">33915568</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon IS, Li C, Son YM, et al. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Reed A, Desai SR, et al. A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae. Sci Transl Med. 2022;14</Citation><ArticleIdList><ArticleId IdType="pubmed">36383686</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandolfi L, Bozzini S, Frangipane V, et al. Neutrophil extracellular traps induce the epithelial-mesenchymal transition: implications in post-COVID-19 fibrosis. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236949</ArticleId><ArticleId IdType="pubmed">34194429</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017;49</Citation><ArticleIdList><ArticleId IdType="pubmed">28232409</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Sancho Figueroa MC, Carrillo G, P&#xe9;rez-Padilla R, et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med. 2010;104:305&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782552</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46:1113&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">26424523</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan FA, Stewart I, Saini G, Robinson KA, Jenkins RG. A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis. Eur Respir J. 2021;59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9202487</ArticleId><ArticleId IdType="pubmed">34588192</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun HJ, Coutavas E, Pine AB, et al. Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection. JCI Insight. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410030</ArticleId><ArticleId IdType="pubmed">34111030</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi SF, Lakhani DA, Sohail AH, et al. Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis. BMJ Open Respir Res. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354761</ArticleId><ArticleId IdType="pubmed">34376400</ArticleId></ArticleIdList></Reference><Reference><Citation>Vad&#xe1;sz I, Husain-Syed F, Dorfm&#xfc;ller P, et al. Severe organising pneumonia following COVID-19. Thorax. 2021;76:201&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">33177230</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18:799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Luger AK, Sonnweber T, Gruber L, et al. Chest CT of lung injury 1 year after COVID-19 pneumonia: The CovILD study. Radiology. 2022;304:462&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988857</ArticleId><ArticleId IdType="pubmed">35348379</ArticleId></ArticleIdList></Reference><Reference><Citation>Aul DR, Gates DJ, Draper DA, et al. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. Respir Med. 2021;188</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425673</ArticleId><ArticleId IdType="pubmed">34536697</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J. 2021;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637181</ArticleId><ArticleId IdType="pubmed">34857587</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Shen C, Wang L, et al. Pulmonary fibrosis and its related factors in discharged patients with new coronavirus pneumonia: a cohort study. Respir Res. 2021;22:203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8267229</ArticleId><ArticleId IdType="pubmed">34243776</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild JM, Porter JC, Molyneaux PL, et al. Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID) BMJ Open Respir Res. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461362</ArticleId><ArticleId IdType="pubmed">34556492</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131:954&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">17426195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(suppl 5):v1&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">18757459</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758541</ArticleId><ArticleId IdType="pubmed">32943404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Rosin NL, Arora R, et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat Med. 2022;28:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799469</ArticleId><ArticleId IdType="pubmed">34782790</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser E, Denney L, Blirando K, et al. Type-1 IFN primed monocytes in pathogenesis of idiopathic pulmonary fibrosis. bioRxiv. 2020 doi: 10.1101/2020.01.16.908749. published online Jan 17. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.01.16.908749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhooria S, Chaudhary S, Sehgal IS, et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Eur Respir J. 2022;59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8850687</ArticleId><ArticleId IdType="pubmed">34887325</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sadeleer LJ, Hermans F, De Dycker E, et al. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur Respir J. 2020;55</Citation><ArticleIdList><ArticleId IdType="pubmed">31949120</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchi C, Sebastiani M, Cassone G, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review. J Clin Med. 2020;9:407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073957</ArticleId><ArticleId IdType="pubmed">32028635</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagata A, Arita M, Tachibana H, et al. Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. Respir Res. 2021;22:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8059166</ArticleId><ArticleId IdType="pubmed">33879137</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelarden I, Nguyen J, Gao J, et al. Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes. Hum Pathol. 2021;113:92&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8159767</ArticleId><ArticleId IdType="pubmed">33905777</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108318</ArticleId><ArticleId IdType="pubmed">15494274</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan FA, Stewart I, Fabbri L, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021;76:907&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">33579777</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9:1407&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409066</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Milara J, Hernandez G, Ballester B, et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res. 2018;19:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801676</ArticleId><ArticleId IdType="pubmed">29409529</ArticleId></ArticleIdList></Reference><Reference><Citation>Le TT, Karmouty-Quintana H, Melicoff E, et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol. 2014;193:3755&#x2013;3768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169999</ArticleId><ArticleId IdType="pubmed">25172494</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam BS, Morris RS, Bramante CT, et al. mTOR inhibition in COVID-19: a commentary and review of efficacy in RNA viruses. J Med Virol. 2021;93:1843&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8159020</ArticleId><ArticleId IdType="pubmed">33314219</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Levi M, Hunt BJ. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med. 2022;10:214&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8616572</ArticleId><ArticleId IdType="pubmed">34838161</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway EM, Mackman N, Warren RQ, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022;22:639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362465</ArticleId><ArticleId IdType="pubmed">35931818</ArticleId></ArticleIdList></Reference><Reference><Citation>Aktaa S, Wu J, Nadarajah R, et al. Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: multi-sourced population-based health records cohort study. Thromb Res. 2021;202:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938753</ArticleId><ArticleId IdType="pubmed">33711754</ArticleId></ArticleIdList></Reference><Reference><Citation>Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832247</ArticleId><ArticleId IdType="pubmed">33341155</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47:60&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674575</ArticleId><ArticleId IdType="pubmed">33211135</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir-McCall JR, Galea G, Mun Mak S, et al. Vascular thrombosis in severe COVID-19 requiring extracorporeal membrane oxygenation: a multicenter study. Crit Care Med. 2022;50:624&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8923278</ArticleId><ArticleId IdType="pubmed">34582412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir&#xf3; &#xd2;, Llorens P, Jim&#xe9;nez S, et al. Frequency of five cardiovascular/hemostatic entities as primary manifestations of SARS-CoV-2 infection: results of the UMC-19-S2. Int J Cardiol. 2021;330:268&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846881</ArticleId><ArticleId IdType="pubmed">33529670</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M, Engelen MM, Barco S, et al. Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: a systematic review and meta-analysis. Thromb Res. 2022;209:94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648604</ArticleId><ArticleId IdType="pubmed">34896917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho FK, Man KKC, Toshner M, et al. Thromboembolic risk in hospitalized and nonhospitalized COVID-19 patients: a self-controlled case series analysis of a nationwide cohort. Mayo Clin Proc. 2021;96:2587&#x2013;2597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8282478</ArticleId><ArticleId IdType="pubmed">34607634</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. Radiology. 2020;296:E186&#x2013;E188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233384</ArticleId><ArticleId IdType="pubmed">32324103</ArticleId></ArticleIdList></Reference><Reference><Citation>Benito N, Filella D, Mateo J, et al. Pulmonary thrombosis or embolism in a large cohort of hospitalized patients with Covid-19. Front Med (Lausanne) 2020;7:557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477312</ArticleId><ArticleId IdType="pubmed">32984388</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte MB, Barker R, Kelly PA, et al. Three-month follow-up of pulmonary embolism in patients with COVID-19. Thromb Res. 2021;201:113&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7908844</ArticleId><ArticleId IdType="pubmed">33662797</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman J, Boubriak I, Jenkins D, et al. Rising COVID-19 related acute pulmonary emboli but falling national chronic thromboembolic pulmonary hypertension referrals from a large national dataset. ERJ Open Res. 2021;7:00431&#x2013;02021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8419584</ArticleId><ArticleId IdType="pubmed">34646880</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124:1973&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pubmed">21969018</ArticleId></ArticleIdList></Reference><Reference><Citation>Desborough MJR, Doyle AJ, Griffiths A, Retter A, Breen KA, Hunt BJ. Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom. Thromb Res. 2020;193:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256551</ArticleId><ArticleId IdType="pubmed">32485437</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam LF, Kroft LJM, van der Wal LI, et al. Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? Thromb Res. 2020;193:86&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7274953</ArticleId><ArticleId IdType="pubmed">32531548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gul MH, Htun ZM, de Jesus Perez V, et al. Predictors and outcomes of acute pulmonary embolism in COVID-19; insights from US National COVID cohort collaborative. Respir Res. 2023;24:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9942071</ArticleId><ArticleId IdType="pubmed">36810085</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides SV, Barco S, Rosenkranz S, et al. Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. J Thromb Thrombolysis. 2016;42:600&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5040729</ArticleId><ArticleId IdType="pubmed">27577542</ArticleId></ArticleIdList></Reference><Reference><Citation>Valerio L, Mavromanoli AC, Barco S, et al. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J. 2022;43:3387&#x2013;3398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9492241</ArticleId><ArticleId IdType="pubmed">35484821</ArticleId></ArticleIdList></Reference><Reference><Citation>Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33:2156&#x2013;2168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7463226</ArticleId><ArticleId IdType="pubmed">32879413</ArticleId></ArticleIdList></Reference><Reference><Citation>Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20:1135&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7279758</ArticleId><ArticleId IdType="pubmed">32526193</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-P&#xe9;rez L, Fortes J, Soto C, et al. Histiocytic hyperplasia with hemophagocytosis and acute alveolar damage in COVID-19 infection. Mod Pathol. 2020;33:2139&#x2013;2146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333227</ArticleId><ArticleId IdType="pubmed">32620916</ArticleId></ArticleIdList></Reference><Reference><Citation>Grist JT, Collier GJ, Walters H, et al. Lung abnormalities detected with hyperpolarized 129Xe MRI in patients with long COVID. Radiology. 2022;305:709&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134268</ArticleId><ArticleId IdType="pubmed">35608443</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel BV, Arachchillage DJ, Ridge CA, et al. Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations. Am J Respir Crit Care Med. 2020;202:690&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462405</ArticleId><ArticleId IdType="pubmed">32667207</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20:172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Toshner MR, Gamble C, Baillie JK, et al. Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial. medRxiv. 2022 doi: 10.1101/2022.12.07.22283175. published online Dec 7. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.12.07.22283175</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021;9:699&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241313</ArticleId><ArticleId IdType="pubmed">33676593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskaran K, Rentsch CT, Hickman G, et al. Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: a cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. PLoS Med. 2022;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789178</ArticleId><ArticleId IdType="pubmed">35077449</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip KEJ, Buttery S, Williams P, et al. Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey. BMJ Open Respir Res. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8762134</ArticleId><ArticleId IdType="pubmed">35027428</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin L, Savale L, Pham T, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021;325:1525&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7970386</ArticleId><ArticleId IdType="pubmed">33729425</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s-Telles A, L&#xf3;pez-Romero S, Figueroa-Hurtado E, et al. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. Respir Physiol Neurobiol. 2021;288</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7910142</ArticleId><ArticleId IdType="pubmed">33647535</ArticleId></ArticleIdList></Reference><Reference><Citation>Froidure A, Mahsouli A, Liistro G, et al. Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae. Respir Med. 2021;181</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019490</ArticleId><ArticleId IdType="pubmed">33839588</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui S, Brightling CE. Pathological disease in the lung periphery after acute COVID-19. Lancet Respir Med. 2021;9:1089&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423429</ArticleId><ArticleId IdType="pubmed">34506762</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassar MP, Tunnicliffe EM, Petousi N, et al. Symptom persistence despite improvement in cardiopulmonary health &#x2014; insights from longitudinal CMR, CPET and lung function testing post-COVID-19. EClinicalMedicine. 2021;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8527025</ArticleId><ArticleId IdType="pubmed">34693230</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Wu J, Hao S, et al. Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection. Sci Rep. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5722861</ArticleId><ArticleId IdType="pubmed">29222500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezzerri V, Gentili V, Api M, et al. SARS-CoV-2 viral entry and replication is impaired in cystic fibrosis airways due to ACE2 downregulation. Nat Commun. 2023;14:132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830623</ArticleId><ArticleId IdType="pubmed">36627352</ArticleId></ArticleIdList></Reference><Reference><Citation>Medino P, Alicandro G, Rosazza C, et al. Impact of COVID-19 on lung disease in people with cystic fibrosis: a 6-month follow-up study on respiratory outcomes. Biomedicines. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9687883</ArticleId><ArticleId IdType="pubmed">36359291</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaudszus A, Pavlova M, Rasche M, Baier M, Moeser A, Lorenz M. One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis. BMC Pulm Med. 2022;22:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8943512</ArticleId><ArticleId IdType="pubmed">35331203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007;297:1772&#x2013;1774.</Citation><ArticleIdList><ArticleId IdType="pubmed">17456818</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganotti P, Buoite Stella A, Ajcevic M, et al. Peripheral nerve adaptations to 10 days of horizontal bed rest in healthy young adult males. Am J Physiol Regul Integr Comp Physiol. 2021;321:R495&#x2013;R503.</Citation><ArticleIdList><ArticleId IdType="pubmed">34318712</ArticleId></ArticleIdList></Reference><Reference><Citation>Narici M, Vito G, Franchi M, et al. Impact of sedentarism due to the COVID-19 home confinement on neuromuscular, cardiovascular and metabolic health: physiological and pathophysiological implications and recommendations for physical and nutritional countermeasures. Eur J Sport Sci. 2021;21:614&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">32394816</ArticleId></ArticleIdList></Reference><Reference><Citation>Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310:1591&#x2013;1600.</Citation><ArticleIdList><ArticleId IdType="pubmed">24108501</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuley HJC, Harvey-Dunstan TC, Craner M, et al. Longitudinal changes to quadriceps thickness demonstrate acute sarcopenia following admission to hospital for an exacerbation of chronic respiratory disease. Thorax. 2021;76:726&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">33443216</ArticleId></ArticleIdList></Reference><Reference><Citation>Skj&#xf8;rten I, Ankerstjerne OAW, Trebinjac D, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. Eur Respir J. 2021;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8247555</ArticleId><ArticleId IdType="pubmed">34210791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr A, Dannerbeck L, Lange TJ, et al. Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19. Multidiscip Respir Med. 2021;16:732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893311</ArticleId><ArticleId IdType="pubmed">33623700</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Ma&#xf1;as L, F&#xe9;art C, Mann G, et al. Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci. 2013;68:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598366</ArticleId><ArticleId IdType="pubmed">22511289</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller I, Mancinetti M, Renner A, et al. Frailty assessment for COVID-19 follow-up: a prospective cohort study. BMJ Open Respir Res. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035838</ArticleId><ArticleId IdType="pubmed">35459694</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne KM, Kwan JM, Guler S, et al. Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease. Respirology. 2017;22:728&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">27860036</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342:1032&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">8105269</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuley HJC, Evans RA, Bolton CE, et al. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study. EClinicalMedicine. 2023;57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10005893</ArticleId><ArticleId IdType="pubmed">36936404</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandentorren S, Sma&#xef;li S, Chatignoux E, et al. The effect of social deprivation on the dynamic of SARS-CoV-2 infection in France: a population-based analysis. Lancet Public Health. 2022;7:e240&#x2013;e249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8843336</ArticleId><ArticleId IdType="pubmed">35176246</ArticleId></ArticleIdList></Reference><Reference><Citation>Spathis A, Booth S, Moffat C, et al. The Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim Care Respir Med. 2017;27:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435098</ArticleId><ArticleId IdType="pubmed">28432286</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010;65:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795166</ArticleId><ArticleId IdType="pubmed">19996336</ArticleId></ArticleIdList></Reference><Reference><Citation>Banzett RB, O'Donnell CR, Guilfoyle TE, et al. Multidimensional Dyspnea Profile: an instrument for clinical and laboratory research. Eur Respir J. 2015;45:1681&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4450151</ArticleId><ArticleId IdType="pubmed">25792641</ArticleId></ArticleIdList></Reference><Reference><Citation>Grist JT, Collier GJ, Walters H, et al. Lung abnormalities detected with hyperpolarized 129Xe MRI in patients with long COVID. Radiology. 2022;305:709&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134268</ArticleId><ArticleId IdType="pubmed">35608443</ArticleId></ArticleIdList></Reference><Reference><Citation>Hameed S, Khan AF, Khan S. Electrodiagnostic findings in COVID-19 patients: a single center experience. Clin Neurophysiol. 2021;132:3019&#x2013;3024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8513511</ArticleId><ArticleId IdType="pubmed">34717222</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockley JA, Alhuthail EA, Coney AM, et al. Lung function and breathing patterns in hospitalised COVID-19 survivors: a review of post-COVID-19 Clinics. Respir Res. 2021;22:255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8474952</ArticleId><ArticleId IdType="pubmed">34579722</ArticleId></ArticleIdList></Reference><Reference><Citation>Heightman M, Prashar J, Hillman TE, et al. Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. BMJ Open Respir Res. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8587466</ArticleId><ArticleId IdType="pubmed">34764200</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammatopoulou EP, Skordilis EK, Georgoudis G, et al. Hyperventilation in asthma: a validation study of the Nijmegen Questionnaire&#x2014;NQ. J Asthma. 2014;51:839&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">24823322</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd S, Walsted ES, Grillo L, Livingston R, Menzies-Gow A, Hull JH. Novel assessment tool to detect breathing pattern disorder in patients with refractory asthma. Respirology. 2018;23:284&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">28905471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hylton H, Long A, Francis C, et al. Real-world use of the Breathing Pattern Assessment Tool in assessment of breathlessness post-COVID-19. Clin Med (Lond) 2022;22:376&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345218</ArticleId><ArticleId IdType="pubmed">35760447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu MF, Mani-Babu S, Degani-Costa LH, et al. Cardiopulmonary exercise testing in the assessment of dysfunctional breathing. Front Physiol. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7873943</ArticleId><ArticleId IdType="pubmed">33584339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xe9;sard I, Genecand L, Altarelli M, et al. Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in &#x2018;long COVID&#x2019; patients with persistent dyspnoea. BMJ Open Respir Res. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8968537</ArticleId><ArticleId IdType="pubmed">35354589</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Sun K, Tahir P, et al. Use of cardiopulmonary exercise testing to evaluate long COVID-19 symptoms in adults: a systematic review and meta-analysis. JAMA Netw Open. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557896</ArticleId><ArticleId IdType="pubmed">36223120</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan T, Brett SJ, Stokes T. Rehabilitation after critical illness: summary of NICE guidance. BMJ. 2009;338:b822.</Citation><ArticleIdList><ArticleId IdType="pubmed">19321554</ArticleId></ArticleIdList></Reference><Reference><Citation>The Faculty of Intensive Care Medicine  FICM position statement and provisional guidance: recovery and rehabilitation for patients following the pandemic. May 2020. https://www.cc3n.org.uk/uploads/9/8/4/2/98425184/ficm_rehab_provisional_guidance.pdf</Citation></Reference><Reference><Citation>Connolly B, Milton-Cole R, Adams C, et al. Recovery, rehabilitation and follow-up services following critical illness: an updated UK national cross-sectional survey and progress report. BMJ Open. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491421</ArticleId><ArticleId IdType="pubmed">34607869</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown SM, Bose S, Banner-Goodspeed V, et al. Approaches to addressing post-intensive care syndrome among intensive care unit survivors. A narrative review. Ann Am Thorac Soc. 2019;16:947&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">31162935</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield-Robinson OJ, Lewis SR, Smith AF, McPeake J, Alderson P. Follow-up services for improving long-term outcomes in intensive care unit (ICU) survivors. Cochrane Database Syst Rev. 2018;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517170</ArticleId><ArticleId IdType="pubmed">30388297</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly B, Salisbury L, O'Neill B, et al. Exercise rehabilitation following intensive care unit discharge for recovery from critical illness. Cochrane Database Syst Rev. 2015;2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517154</ArticleId><ArticleId IdType="pubmed">26098746</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner-Stokes L, Corner EJ, Siegert RJ, et al. The post-ICU presentation screen (PICUPS) and rehabilitation prescription (RP) for intensive care survivors part I: development and preliminary clinimetric evaluation. J Intensive Care Soc. 2022;23:253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411778</ArticleId><ArticleId IdType="pubmed">36033253</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10008021</ArticleId><ArticleId IdType="pubmed">25705944</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094410</ArticleId><ArticleId IdType="pubmed">34559419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;nig E, MacKenzie A, Peacock AJ, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. Eur Heart J. 2021;42:2284&#x2013;2295.</Citation><ArticleIdList><ArticleId IdType="pubmed">33232470</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddocks M, Kon SS, Canavan JL, et al. Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study. Thorax. 2016;71:988&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099190</ArticleId><ArticleId IdType="pubmed">27293209</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlucci A, Paneroni M, Carotenuto M, et al. Prevalence of exercise-induced oxygen desaturation after recovery from SARS-CoV-2 pneumonia and use of lung ultrasound to predict need for pulmonary rehabilitation. Pulmonology. 2021 doi: 10.1016/j.pulmoe.2021.05.008. published online Jun 4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pulmoe.2021.05.008</ArticleId><ArticleId IdType="pmc">PMC8175480</ArticleId><ArticleId IdType="pubmed">34247995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez J, Ben&#xed;tez ID, Carmona P, et al. Pulmonary function and radiologic features in survivors of critical COVID-19: a 3-month prospective cohort. Chest. 2021;160:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930807</ArticleId><ArticleId IdType="pubmed">33676998</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs SS, Krishnan JA, Lederer DJ, et al. Home oxygen therapy for adults with chronic lung disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;202:e121&#x2013;e141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7667898</ArticleId><ArticleId IdType="pubmed">33185464</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: Interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society and American Thoracic Society-coordinated international task force. Eur Respir J. 2020;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427118</ArticleId><ArticleId IdType="pubmed">32817258</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh SJBC, Nolan C, Harvey-Dunstan T, Connolly B, Man W, Walker P. Delivering rehabilitation to patients surviving COVID-19 using an adapted pulmonary rehabilitation approach &#x2013; BTS guidance. Sept 16, 2020. https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/pulmonary-rehabilitation-for-covid-19-patients/</Citation></Reference><Reference><Citation>Zheng B, Daines L, Han Q, et al. Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis. Eur Respir Rev. 2022;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9724798</ArticleId><ArticleId IdType="pubmed">36323418</ArticleId></ArticleIdList></Reference><Reference><Citation>Houchen-Wolloff L, Poinasamy K, Holmes K, et al. Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. Thorax. 2022;77:717&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9209667</ArticleId><ArticleId IdType="pubmed">35354642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gloeckl R, Leitl D, Jarosch I, et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res. 2021;7:00108&#x2013;02021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7957293</ArticleId><ArticleId IdType="pubmed">34095290</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Xia W, Zhan C, et al. A telerehabilitation programme in post-discharge COVID-19 patients (TERECO): a randomised controlled trial. Thorax. 2022;77:697&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8318721</ArticleId><ArticleId IdType="pubmed">34312316</ArticleId></ArticleIdList></Reference><Reference><Citation>Daynes E, Gerlis C, Chaplin E, Gardiner N, Singh SJ. Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition &#x2014; a cohort study. Chron Respir Dis. 2021;18 14799731211015691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8114752</ArticleId><ArticleId IdType="pubmed">33957805</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinert G, M&#xfc;ller D, Wagner P, et al. Pulmonary rehabilitation in SARS-CoV-2: a systematic review and meta-analysis of post-acute patients. Diagnostics (Basel) 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9776761</ArticleId><ArticleId IdType="pubmed">36553039</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip KEJ, Owles H, McVey S, et al. An online breathing and wellbeing programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group, single-blind, randomised controlled trial. Lancet Respir Med. 2022;10:851&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9045747</ArticleId><ArticleId IdType="pubmed">35489367</ArticleId></ArticleIdList></Reference><Reference><Citation>McNarry MA, Berg RMG, Shelley J, et al. Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial. Eur Respir J. 2022;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8900538</ArticleId><ArticleId IdType="pubmed">35236727</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11371308</ArticleId><ArticleId IdType="pubmed">23076942</ArticleId></ArticleIdList></Reference><Reference><Citation>Santino TA, Chaves GS, Freitas DA, Fregonezi GA, Mendon&#xe7;a KM. Breathing exercises for adults with asthma. Cochrane Database Syst Rev. 2020;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096190</ArticleId><ArticleId IdType="pubmed">32212422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruton A, Lee A, Yardley L, et al. Physiotherapy breathing retraining for asthma: a randomised controlled trial. Lancet Respir Med. 2018;6:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757422</ArticleId><ArticleId IdType="pubmed">29248433</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones M, Harvey A, Marston L, O'Connell NE. Breathing exercises for dysfunctional breathing/hyperventilation syndrome in adults. Cochrane Database Syst Rev. 2013;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11379427</ArticleId><ArticleId IdType="pubmed">23728685</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  COVID-19 clinical management: living guidance, 25 January 2021. Jan 25, 2021. https://apps.who.int/iris/handle/10665/338882</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>